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Lipoxin & (LXA.,) is a biologically active compound produced from arachidonic acid via interactions of lipoxygenases. Incubation of LXA, either 
with human neutrophils or with the neutrophil microsomes leads to formation of a polar compound on a reverse-phase high-performance liquid 
chromatography. We have identified the metabolite as 20-hydroxy-LXA,, a novel metabolite of arachidonic acid, on the basis of ultraviolet 
spectrometry and gas chromatography-mass pectrometry. The LXA, w-hydroxylation requires both molecular oxygen and NADPH, and is 
inhibited by carbon monoxide, by antibodies raised against NADPH-cytochrome P-450 reductase, or competitively by leukotriene B4 (LTB,) and 
LTB,, substrates of LTB, w-hydroxylase. These findings indicate that the formation of 20-hydroxy-LXA, is catalyzed by a neutrophil cytochrome 
P-450, the LTB, o-hydroxylase. 
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1. INTRODUCTION 
Unesterified arachidonic acid, released upon cell 
stimulation, is converted via lipoxygenase pathways to 
biologically potent products, leukotrienes and lipoxins 
[l-3]. The leukotrienes, produced through the 5-lipoxy- 
genase pathway, participate in host defense reactions 
and play a role in immediate hypersensitivity and in- 
flammation [l]. Interactions of 5-, 12- and 15-lipoxyge- 
nases lead to the formation of the lipoxins, a novel class 
of biologically active eicosanoids with a conjugated 
tetraene as a common structural feature [l-3]. Among 
them, lipoxin Ad (LXA,) is one of the most potent com- 
pound and possesses a diverse array of biological activ- 
ities such as vasodilation [1,3], bronchoconstriction 
[1,3], inhibition of natural killer cell cytotoxicity [1,3], 
activation of isolated protein kinase C [4] and enhance- 
ment of the growth of myeloid progenitor cells [5]. In 
addition, recent studies indicate that LXA4 displays ac- 
tions counterregulatory to the proinflammatory effects 
of the leukotrienes. LXA, inhibits leukotriene B, 
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(LTB,)-induced inflammation in the hamster cheek 
pouch [6] and prior exposure of neutrophils to the 
lipoxin blocks the chemotactic response to LTB, [7,8]. 
Both the cellular and in vivo actions of leukotriene D, 
in renal microcirculation are antagonized by LXA, [9]. 
These activities suggest hat LXA, may be associated 
with human diseases. The lipoxin is indeed detected in 
bronchoalveolar lavage fluids obtained from patients 
with pulmonary diseases [lo]. 
Rapid conversion to inactive compounds should be 
expected for such potent molecules as a mechanism to 
terminate their actions. There have been considerable 
studies on the metabolism of the leukotrienes. Human 
neutrophils rapidly metabolize LTB, via w-oxidation to 
20-hydroxy-LTB, (20-OH-LTB,) and subsequently to 
20-carboxy-LTB, [l l-141, reactions which are catalyzed 
by a microsomal LTB, o-hydroxylase, a cytochrome 
P-450 (P-450) with a high affinity for LTB, (to be desig- 
nated P-450,,,,) [ 15-201. LTB, is also w-oxidized by rat 
hepatocytes [21-231, in which 20-carboxy-LTB, formed 
is further metabolized via /?-oxidation along the w-ter- 
minus [24]. w-Hydroxylation followed by oxidation to 
the dicarboxylic acid and /&oxidation from the o-end 
has also been recognized as the major pathway for the 
degradation of the cysteinyl leukotrienes [25-291. 
Although increasing interest has been paid to the bio- 
logical activities of LXA,, little is presently known 
about the metabolic fate of this potent compound. 
Boucher et al. [30] have shown, in the only report on this 
subject, that LXA, is converted to a more polar meta- 
bolite by incubating with human intact leukocytes or 
with rat liver microsomes, and the compound is charac- 
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terized as retaining the conjugated tetraene structure 
indicated by ultraviolet (UV) spectrometry but the pre- 
cise structural features are not elucidated. 
In the present study we isolated and identified a novel 
metabolite of arachidonic acid, 20-OH-LXA,, formed 
by incubating LXA, with human neutrophils or with the 
neutrophil microsomes. The formation of 20-OH-LXA, 
seems to be catalyzed by the LTB4 w-hydroxylase (P- 
450 ). LTEW 
2. EXPERIMENTAL 
2.1. Materials 
Human neutrophils were isolated from the blood of healthy volun- 
teers by dextran sedimentation, hypotonic lysis and the Conray-Ficoll 
method, and the neutrophil microsomes and cytosols were prepared 
by differential centrifugation technique as previously described [I 71. 
LXA, was purchased from Cascade Biochem., UK; LTB, from 
Cayman Chemical Co., Ann Arbor, USA; lauric acid from Sigma 
Chemical Co., St. Louis, USA; palmitic acid from Wako Pure Chem- 
ical Industry, Osaka, Japan; stearic acid from Nacalai Tesque Inc., 
Kyoto, Japan; NADPH from Oriental Yeast Co., Tokyo, Japan. All 
other reagents were of the highest purity commercially available. An- 
tibodies raised against NADPH-cytochrome P-450 reductase in rat 
liver microsomes were prepared as previously described [17]. 
2.2. Measurement of LXA, w-hydroxylase activity 
Human neutrophil microsomes suspended in 100 ~1 of 100 mM 
potassium phosphate, pH 7.5, were incubated for the indicated time 
at 37°C with LXAI in the presence of 25 PM NADPH. The reaction 
mixture was terminated by addition of 100 ~1 of methanol. After 
centrifugation, 20 ~1 of the supernatant was diluted with 80 ~1 of 
acetonitrile/water/phosphoric acid (15:85:0.00425, v/v) and the sample 
(100 ~1) was subjected to reverse-phase high-performance liquid 
chromatography (RP-HPLC). This was carried out using a Shimadzu 
LCdA gradient system and a Chemcosorb 5-ODS-H column (5 pm, 
4.6 x 150 mm; Chemco Scientific Co., Osaka) with continuous moni- 
toring for ultraviolet absorbance at 301 nm. A flow rate was main- 
tained at 1 .O mhmin. Elution was performed isocratically with acetoni- 
trile/water/phosphoric acid (15:85:0.00425, v/v) for the first 5 mm, 
followed by a linear increase in acetonitrile to 100% for the next 35 
min. Typical elution times for LXA, and 20-OH-LXA, were 23.0 and 
16.8 min. respectively. Integrated peak areas were used for quantita- 
tive analyses of LX& and its metabohte. 
2.3. IdentiJication of 20-OH-LXA, 
The 20-OH-LXA,, formed by human neutrophils or by the neutro- 
phi1 microsomes, was identified by UV spectrometry and GC-MS. The 
UV spectrum of the 20-OH-LXA, separated by RP-HPLC was re- 
corded in methanol using a Hitachi 340 UV/vis spectrophotometer. 
The lipid was methylated with ethereal diazomethane and subjected 
to straight-phase HPLC using Chemcosorb 5-Si (4.6 x 150 mm. 
Chemco Scientific Co., Osaka). The methyl ester was eluted isocrati- 
tally at a flow rate of 1.0 ml/mm with n-hexanel2-propanol (80:20, 
v/v). Typical elution times for the methyl ester derivatives of LXA, and 
20-OH-LXA, were 4.3 and 15.0 min, respectively. The methyl esters 
were converted to their trimethylsilyl ether derivatives prior to gas 
chromatography-mass pectrometry (GC-MS) analyses with hexa- 
methyldisilazane/trimethylchlorosilane. Th  samples were dissolved in 
hexane and injected to a gas chromatography/mass pectrometer 
equipped with a fused silica column (NB-1, equivalent o OV-1, GL 
Sciences Inc., Tokyo) (30 m x 0.25 mm). The mass spectrometer 
employed was a JEOL JMS-DX 300 double-focusing model interfaced 
to a JEOL JMA-3500 data system (Tokyo, Japan). The temperature 
of the injector and the column were kept at 300 and 280°C respec- 
tively. The equivalent chain lengths (C-values) of the compounds on 
GC were determined using methyl ester derivatives of long-chain fatty 
206 
acids (chain length: 16,18,20,22,24,26,28 and 30) as standards. The 
mass spectra were obtained by electron impact ionization with an 
ionization energy of 30eV. 
3. RESULTS AND DISCUSSION 
Incubation of LXA4 with human neutrophils led to 
formation of a more polar product (compound I) with 
an elution time of 16.8 min on an RP-HPLC as detected 
by UV absorption at 301 nm (data not shown). The 
compound was also formed coincident with disappear- 
ance of LXA4, when LXA, was incubated with the neu- 
trophil microsomes under aerobic conditions in the 
presence of NADPH (Fig. 1). Similar analyses of the 
incubated samples, either with the neutrophils or with 
the microsomes, at different wavelengths (320, 270 and 
230 nm) showed essentially the same profiles in RP- 
HPLC as those at 301 nm with no indication for forma- 
tion of other metabolites (data not shown), suggesting 
that LXA, is converted solely to compound I under the 
conditions used in the present study. 
To identify this novel metabolite, we performed UV 
and GC-MS analyses. The UV spectrum of compound 
I showed a triplet of absorption bands at 288, 301 and 
316 nm (Fig. 2a), which is identical to that of LXA, 
(Fig. 2b). This suggests that the conjugated tetraene 
structure in LXA, is retained in the metabolite. Gas 
chromatographic analysis of the trimethylsilyl ether, 
methyl ester derivative of compound I showed a peak 
with a C-value of 26.9 (data not shown). The mass 
spectrum (Fig. 3A) was characterized by ions at m/e: 
670 (M’), 580 (M’-90, loss of trimethylsilanol), 490 
[M+-(90+90)], 482, 467 [M+- 2031, 377 [467-901, 
305 [Me,SiO+=CH-CH(OSiMe3)-(CH,),-COOMe], 261 
[Me,SiO’=CH-(CH,),-CH,-OSiMe,l, 215 [305-901, 203 
[base peak, Me$iO+=CH-(CH& COOMe], 171 [261- 
90 and 203-CH,OH], 129 and 113 [203-901. Several ions 
were the same as those for the corresponding derivative 
of LXA, at m/e 482 [M’-100; probably rearrangement 
followed by loss of O=HC-(CH,),-CH,, according to 
ref. 311, 305, 215, 203, 129 and 113 (Fig. 3A and B), 
suggesting that the structure of the C-l through C-l 5 
part of compound I is the same as that of LXA,. Other 
remaining ions (m/e 670, 580, 490, 467, 377 and 261) 
were shifted 88 mass units up in comparison with ions 
in the spectrum of LXA,, a finding consistent with the 
presence of an additional hydroxyl group at a position 
beyond C-l 6. The difference in C-value between a hy- 
droxylated fatty acid metabolite and the parent com- 
pound is often used to determine the site of hydroxyla- 
tion [l 1,32-351. The C-value for the trimethylsilyl ether 
methyl ester of compound I (26.9) was 3.0 C longer than 
that for the corresponding derivative of LXA, (23.9, 
data not shown). The difference is consistent with those 
between 5S,12S,20-trihydroxytetraenoic acid and 
5S, 12Sdihydroxytetraenoic acid (3.0 C) [35], between 
20-OH-LTB, and LTB, (3.1 C) [ll], and between 20- 
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Fig. 1. High-performance liquid chromatograms of LXA and a prod- 
uct (compound I) obtained by incubating human neutrophil micro- 
somes with LXA. LXA (6.0 PM) was incubated for 0 min (A) or for 
15 min (B) with 500 &ml human neutrophil microsomes in the pres- 
ence of 25 PM NADPH. The samples were subjected to RP-HPLC as 
described under Experimental. 
hydroxy-prostaglandin B and prostaglandin B (3.1 C) 
[32-341. The finding indicates that the additional hy- 
droxyl group is located at the C20 position. Taken to- 
gether with the UV and GC-MS analyses, compound I 
was identified as 20-OH-LXA. 
Thus, we isolated and identified a novel metabolite of 
LXA, i.e. 20-OH-LXA, from the incubation of LXA 
with human neutrophils or with the neutrophil micro- 
somes. In contrast to the present findings, there have 
been studies reporting that lipoxins including LXA are 
not transformed via w-oxidation by intact human neu- 
trophils [36] or in a cell-free system of the neutrophils 
[16]. Boucher et al., however, have reported that the 
incubation of LXA with human neutrophils leads to 
the formation of a more polar metabolite [30], which 
appears to be 20-OH-LXA. Although the reason for 
this discrepancy is presently unclear, it could be ex- 
plained by the difference in analytical procedures in- 
cluding solvents used in HPLC, and by a relatively low 
rate of the 20-OH-LXA formation compared with that 
of the LTB w-hydroxylation (see below). By incubating 
with human neutrophils or the microsomes, LXA was 
converted solely to 20-OH-LXA: we could not obtain 
any evidence for the formation of the 1Phydroxy deriv- 
ative of LXA using RP-HPLC and GC-MS. This is not 
surprising because human neutrophils possess only an 
LTB w-hydroxylase [l l-171, responsible for the LXA 
w-hydroxylation as described below, while both w- and 
(w- I)-hydroxylase activities for LTB exist in rat liver 
microsomes [21]; both (w-l)- and (w-2)-hydroxylase ac- 
tivities in rat polymorphonuclear leukocytes [37]. 
We further characterized the LXA w-hydroxylation 
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Fig. 2. Ultraviolet spectra of a metabolite of LXA (compound I) (a) 
and LXA (b). 
by human neutrophil microsomes to clarify the enzyme 
responsible for the reaction. The decrease in LXA cor- 
responded to the formation of 20-OH-LXA at any time 
studied (data not shown), suggesting that LXA is stoi- 
chiometrically converted to 20-OH-LXA. The LXA- 
hydroxylating activity was proportional to an incuba- 
tion time of up to 60 min and to the concentration of 
the microsomal protein below 3.0 mg/ml (data not 
shown), while the activity was not detected by using 
human neutrophil cytosols (data not shown). The rate 
of the 20-OH-LXA formation at 10 ,uM of LXA was 
29 + 2 pmol/min/mg of microsomal protein (n = 5), 
which is approximately 5510% of the rate for the LTB 
w-hydroxylation by human neutrophil microsomes 
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Fig. 3. Mass spectra of the trimethylsilyl ether methyl ester derivatives of a metabolite of LXA, (compound I) (A) and LX& (B). Compound I 
was isolated and derivatized as described under Experimental. 
[17,18]. When reactions were run at 0°C in the absence 
of NADPH or using microsomes pretreated for 10 min 
at 80°C no product was formed (Table I). As shown in 
Table I, a negligible activity to o-hydroxylate LXA4 
was observed under anaerobic conditions, indicating 
that the reaction requires molecular oxygen. The hy- 
droxylation was strongly inhibited by carbon monoxide 
(Table I). The findings of the localization in the micro- 
somes, the requirement of O2 and NADPH, and the 
inhibition by CO, suggest hat a P-450 is involved in the 
208 
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reaction. The involvement is further supported by inhi- 
bition of the reaction by antibodies raised against 
NADPH-P-450 reductase (Table I). To confirm that the 
P-450 is the LTB, w-hydroxylase, we carried out the 
following experiments. LTB,, a substrate of P-450LTBo, 
inhibited the LXA, w-hydroxylation by the neutrophil 
microsomes (Table I). LTB,, a good substrate but with 
a lesser affinity than that of LTB, [19], also possessed 
an inhibitory activity but to a lesser extent (Table I). 
The inhibitions by LTB, and by LTB, were restored by 
increasing the concentrations of LXA, (data not 
shown), suggesting that the inhibitors act in a competi- 
tive manner. Various fatty acids including lauric acid 
and PGA,, all of which are not substrates for P-450,,,, 
[16,17,19], did not affect the reaction (Table I). The 
formation of 20-OH-LXA, by human neutrophils is, 
thus, catalyzed by the LTB, w- hydroxylase (P-450,,,,), 
whereas the formation of a polar metabolite by incubat- 
ing LXA, with rat liver microsomes seems to be cata- 
lyzed by a P-450 but not by the one(s) responsible for 
LTB, metabolism [30]. Since LXA, antagonizes the ac- 
tions of LTB, towards neutrophils [7,8], the competitive 
inhibition by LTB, of the neutrophil-dependent LXA, 
w-hydroxylation may suggest a regulation in the inter- 
Table I 
Lipoxin & w-hydroxylation by human neutrophil microsomes under 
various conditions 
Condition LXA, w-hydroxylase 
activity (%) 
Control 100 
Heat-treated microsomes” 0 
Without NADPH 0 
Anaerobic 2 
Anti-NADPH-P-450 reductase IgG (100 &ml) 27 
Non-immune IgG (100 pg/ml) 103 
CO/O2 (80/20, W) 12 
LTB, (1 PM) 28 
LTB, (3 PM) 9 
LTB, (1 PM) 61 
LTB, (3 PM) 18 
Laurie acid (3 PM) 106 
Stearic acid (3 PM) 102 
PGA, (3 PM) 94 
PGE, (3 PM) 97 
a The microsomes were pretreated for 10 min at 80” C. 
b The microsomes were deoxygenated under a stream of nitrogen fol- 
lowed by incubation with 10 mM glucose, glucose oxidase (50&m]), 
and catalase (100 @ml) for 10 min at 25°C before starting the 
reaction. 
Human neutrophil microsomes (50 pg) suspended in 100 ~1 of the 
phosphate-buffered solution, pH 7.5, was incubated for 15 min at 
37°C with LXA, (6.0 PM) in the presence or absence of NADPH (25 
PM) under the indicated conditions. The LXA, w-hydroxylating activ- 
ity was determined as described under Experimental Procedures. Data 
represent mean values of two experiments. The activity under aerobic 
conditions in the absence of the inhibitors (18 nmol/min/mg protein) 
is set at 100%. 
action between these active substances: actions of LXA, 
can be regulated by LTB, through the competition at 
the common metabolizing enzyme. 
Since lipoxin B, (LXB,) is also converted to 20-hy- 
droxy-LXB, by human neutrophil microsomes (Y. 
Mizukami and H. Sumimoto, unpublished observa- 
tion), the conversion to 20-hydroxy metabolites may be 
important to eliminate lipoxins in the organism. The 
w-hydroxylation is an initial step in the formation of the 
dicarboxylic acid required for subsequent /?-oxidation 
from the o-end, and this oxidation pathway has now 
been recognized as the major pathway for the degrada- 
tion and elimination of the leukotrienes [24,2629]. 
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